ECSP22033601A - Formulación de anticuerpo que contiene crizanlizumab - Google Patents

Formulación de anticuerpo que contiene crizanlizumab

Info

Publication number
ECSP22033601A
ECSP22033601A ECSENADI202233601A ECDI202233601A ECSP22033601A EC SP22033601 A ECSP22033601 A EC SP22033601A EC SENADI202233601 A ECSENADI202233601 A EC SENADI202233601A EC DI202233601 A ECDI202233601 A EC DI202233601A EC SP22033601 A ECSP22033601 A EC SP22033601A
Authority
EC
Ecuador
Prior art keywords
crizanlizumab
formulation containing
antibody formulation
antibody
formulations
Prior art date
Application number
ECSENADI202233601A
Other languages
English (en)
Inventor
Fabian Bickel
Caroline Hilbert
Juergen Sigg
Frieder Kroener
Maja Anko
Aljosa Jelenko
Francois Griaud
Lina Boado
Dirk Chelius
Rajsekhar Paul
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP22033601A publication Critical patent/ECSP22033601A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a nuevas formulaciones farmacéuticas de un anticuerpo contra P-selectina humana, en especial SEG101, o un anticuerpo que tiene como máximo 3 aminoácidos de diferencia respecto de crizanlizumab, procesos para su preparación y usos de las formulaciones.
ECSENADI202233601A 2019-10-30 2022-04-27 Formulación de anticuerpo que contiene crizanlizumab ECSP22033601A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962927720P 2019-10-30 2019-10-30
US201962927716P 2019-10-30 2019-10-30
US201962933692P 2019-11-11 2019-11-11
US201962936269P 2019-11-15 2019-11-15

Publications (1)

Publication Number Publication Date
ECSP22033601A true ECSP22033601A (es) 2022-05-31

Family

ID=73544317

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202233601A ECSP22033601A (es) 2019-10-30 2022-04-27 Formulación de anticuerpo que contiene crizanlizumab

Country Status (16)

Country Link
US (1) US20220378912A1 (es)
EP (1) EP4051236A1 (es)
JP (1) JP2023501155A (es)
KR (1) KR20220092917A (es)
CN (1) CN114828826A (es)
BR (1) BR112022008097A2 (es)
CA (1) CA3158921A1 (es)
CL (1) CL2022001085A1 (es)
CO (1) CO2022005207A2 (es)
EC (1) ECSP22033601A (es)
IL (1) IL292403A (es)
JO (1) JOP20220097A1 (es)
MX (1) MX2022005044A (es)
PE (1) PE20221276A1 (es)
TW (1) TW202128221A (es)
WO (1) WO2021087050A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2662091T (lt) 2006-12-01 2018-12-10 Novartis Ag Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
JOP20190101A1 (ar) 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
EP3624846A1 (en) * 2017-05-16 2020-03-25 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
EP3762424A1 (en) * 2018-03-08 2021-01-13 Novartis AG Use of an anti-p-selectin antibody

Also Published As

Publication number Publication date
WO2021087050A1 (en) 2021-05-06
MX2022005044A (es) 2022-05-16
EP4051236A1 (en) 2022-09-07
US20220378912A1 (en) 2022-12-01
PE20221276A1 (es) 2022-09-05
BR112022008097A2 (pt) 2022-08-02
TW202128221A (zh) 2021-08-01
AU2020373017A1 (en) 2022-05-19
JOP20220097A1 (ar) 2023-01-30
CA3158921A1 (en) 2021-05-06
KR20220092917A (ko) 2022-07-04
JP2023501155A (ja) 2023-01-18
CO2022005207A2 (es) 2022-05-10
CL2022001085A1 (es) 2023-02-03
IL292403A (en) 2022-06-01
CN114828826A (zh) 2022-07-29

Similar Documents

Publication Publication Date Title
CL2019001686A1 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas.
CL2019003627A1 (es) Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628)
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
CL2018000503A1 (es) Composiciones de insulina de rápida acción
GT201700184A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112020009655A8 (pt) Anticorpo, usos de um anticorpo e uso de uma combinação farmacêutica
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
CL2020001821A1 (es) Formulación de adenovirus del grupo b.
CL2020000897A1 (es) Composición de proteínas de guisante que tiene calidad nutricional mejorada.
BR112017000312A2 (pt) sistema de tratamento da saúde bucal para a aplicação de fosfato de cálcio amorfo, uso de um ou mais aminoácidos básicos, composição, e uso de um ou mais aminoácidos em um sistema de tratamento da saúde bucal
BR112016026660A2 (pt) ?produto extemporâneo para cuidados cosméticos e/ou dermatológicos, e, kit de preparação extemporânea de uma composição cosmética e/ou dermatológica?
BR112017024039B8 (pt) Piroglutamato de vortioxetina, composições farmacêuticas e gel compreendendo o mesmo, método para preparar um gel, e usos do piroglutamato de vortioxetina para fabricação de um medicamento ou gel
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno
BR112019007543A2 (pt) inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
CO2021002085A2 (es) Composiciones de curcuminoides
MX2020004675A (es) Formulaciones de alcohol de seda.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112018070626A2 (pt) formulação farmacêutica, e, composto ou composição para uso, uso, método ou composição
BR112018003945A2 (pt) extrato de gardenia para tonalizar a pele
CO2020016008A2 (es) Formulación de proteína de fusión estable
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas
ECSP22033601A (es) Formulación de anticuerpo que contiene crizanlizumab